Tarlatamab is being studied as a treatment option for patients with previously treated small-cell lung cancer. The treatment has been associated with certain side effects, including neurotoxicity and cytokine release syndrome, although the nature and management of these effects are being explored. It is unclear which patients may benefit most from tarlatamab, but it may potentially emerge as a new standard of care for small-cell lung cancer.